secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-09-18T21:00:21+00:00
Accession:  0001193125-26-395694
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa updates corporate presentation on (Z)-Endoxifen, but no specifics disclosed
--------------------------------------------------------------------------------

- Filed updated corporate presentation on 8-K Sept 18, 2026; no financial or clinical data shown.
- Presentation cover cites (Z)-Endoxifen as potential best-in-class oral SERM/SERD for estrogen-driven diseases.
- Available exhibit excerpt contains only the title slide; operational milestones or guidance not provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526395694/0001193125-26-395694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526395694/atos-20260918.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-395694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer